What sector does Zimmer Biomet belong to?

Zimmer Biomet operates in the Health Care sector, specifically the Health Care Equipment industry, and is listed on the US markets.

What is the current share price of ZBH?

As of the latest available quote, ZBH traded at $93.49. This price is delayed and cached for about 15 minutes.

What is the P/E ratio of ZBH?

Zimmer Biomet has a price-to-earnings (P/E) ratio of about 22.69. The P/E ratio compares the share price to earnings per share and is most useful when compared with sector peers and the company's own history.

What is the market capitalisation of ZBH?

The market capitalisation of Zimmer Biomet is approximately $18.57B.

Is Zimmer Biomet profitable?

For its latest reported financial year, Zimmer Biomet recorded a net profit margin of about 8.57%.

Does ZBH pay a dividend?

Zimmer Biomet currently has a dividend yield of about 1.04%.

What is the return on equity (ROE) of ZBH?

Zimmer Biomet has a return on equity (ROE) of about 5.59%. ROE measures how much profit a company generates relative to shareholders' equity.

What is the 52-week high and low of ZBH?

Over the past 52 weeks, ZBH has traded between a low of $79.12 and a high of $106.88.

Zimmer Biomet

ZBH US Health Care Health Care Equipment

S&P 500

$93.49

+1.14%

Delayed · cached 15 min

Fair value analysis

ZBH

Zimmer Biomet

$93.49

Close used for this calculation

$89.23Fair value

Financial DNA Score

Profitability · Returns · Balance Sheet · Efficiency · Growth

42/100

Profitability8/25

Returns9/25

Balance Sheet16/25

Efficiency9/25

Growth4/25

Average

Quality radar

Consensus fair value

$89.23

Near FV

▼ -4.6% against the close used

Model range $6.57 – $138.96

The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear$6.57Fair value$89.23Bull$138.96

FairClose

52-week traded range

52W low $79.5852W high $104.26

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading close to the consensus fair value

Zimmer Biomet closed at $93.49, 4.8% above the consensus fair value of $89.23 drawn from 9 valuation models.

Financial DNA score 42/100 — Average. P/E of 26.3x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation

$138.96

+48.6%

Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10

g=8%, r=10%, tg=3%, n=10yr

Graham Number

$72.26

-22.7%

√(22.5 × EPS × BVPS)

EPS=3.55, BVPS=65.38 · outside Graham range (P/E 26.3, P/B 1.4) — asset-light, treat as a rough floor

P/E Fair Value

$71.00

-24.1%

EPS × 20x (sector P/E)

EPS=3.55, Sector P/E=20x

Peter Lynch (PEG)

$6.57

-93.0%

EPS × Growth% (PEG = 1 is fair)

EPS=3.55, g=1.9%

EV/EBITDA

$75.48

-19.3%

(EBITDA × 10x − Net Debt) ÷ Shares

EBITDA=2.19B

Dividend Discount (DDM)

$12.28

-86.9%

D1 ÷ (r − g) where D1 = D0×(1+g)

D0=0.96, r=10%, g=2%

Book Value (P/B)

$24.19

-74.1%

BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]

BVPS=65.38, ROE=5.6%, g=3%, r=10%

Reverse DCF

$93.49

+0.0%

Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV

Implied: 10.9% | Historical: -1.9%

Margin of Safety

$70.56

-24.5%

Avg(DCF, Graham, P/E) × 75% (25% safety buffer)

Avg fair value=94.07, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Fair value analysis

Consensus fair value

Price target range & 52-week position

Valuation summary

All valuation models

Equity Timer